UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 552

Sortiert nach

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

The New England journal of medicine, 2020-10, Vol.383 (15), p.1425-1435

2020

Link zum Volltext

Verfügbarkeit prüfen

Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: Results from the DIALOG study

Diabetes & metabolism, 2015-04, Vol.41 (2), p.116-125

2015

Link zum Volltext

Verfügbarkeit prüfen

Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal

Diabetes & metabolism, 2014-06, Vol.40 (3), p.176-185

2014

Link zum Volltext

Verfügbarkeit prüfen

A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial

Diabetic medicine, 2005-04, Vol.22 (4), p.399-405

2005

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings

Diabetes & metabolism, 2019-12, Vol.45 (6), p.528-535

2019

Link zum Volltext

Verfügbarkeit prüfen

After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?

Diabetes & metabolism, 2017-04, Vol.43, p.2S3-2S12

2017

Link zum Volltext

Verfügbarkeit prüfen

Pharmacological management of type 2 diabetes: the potential of incretin-based therapies

Diabetes, obesity & metabolism, 2011-02, Vol.13 (2), p.99-117

2011

Link zum Volltext

Verfügbarkeit prüfen

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)

European heart journal, 2007-01, Vol.28 (1), p.88-136

2007

Link zum Volltext

Verfügbarkeit prüfen

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes

Diabetes & metabolism, 2020-04, Vol.46 (2), p.110-118

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Pioglitazone Versus Metformin in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Randomized Trial

The journal of clinical endocrinology and metabolism, 2004-12, Vol.89 (12), p.6068-6076

2004

Link zum Volltext

Verfügbarkeit prüfen

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

Diabetes/metabolism research and reviews, 2005-03, Vol.21 (2), p.167-174

2005

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial

Diabetologia, 2013-07, Vol.56 (7), p.1503-1511

2013

Link zum Volltext

Verfügbarkeit prüfen

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

Diabetologia, 2010-07, Vol.53 (7), p.1258-1269

2010

Link zum Volltext

Verfügbarkeit prüfen

Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes

International journal of clinical practice (Esher), 2007-06, Vol.61 (s153), p.1-2

Charbonnel, B.

2007

Link zum Volltext

Verfügbarkeit prüfen

CA-109: Conséquences d'une hypoglycémie sévère sur le contrôle glycémique dans le diabète : analyse du DCCT

Diabetes & metabolism, 2016-03, Vol.42, p.A64-A65

2016

Link zum Volltext

Verfügbarkeit prüfen

Predicting severe hypoglycaemia with self-monitoring of blood glucose in type 1 diabetes

Diabetes & metabolism, 2017-09, Vol.43 (4), p.392-394

2017

Link zum Volltext

Verfügbarkeit prüfen

A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment

Diabetes, obesity & metabolism, 2014-02, Vol.16 (2), p.170-178

2014

Link zum Volltext

Verfügbarkeit prüfen

Insulin therapy for diabetes mellitus: Treatment regimens and associated costs

Diabetes & metabolism, 2012-04, Vol.38 (2), p.156-163

2012

Link zum Volltext

Verfügbarkeit prüfen

Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes

Diabetes, obesity & metabolism, 2015-02, Vol.17 (2), p.170-178

2015

Link zum Volltext

Verfügbarkeit prüfen

Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin? A randomized controlled trial of a DPP4 inhibitor versus insulin secretagogues

Diabetes research and clinical practice, 2016-06, Vol.116, p.26-28

2016

Link zum Volltext

Verfügbarkeit prüfen

Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study

Diabetes & metabolism, 2003-12, Vol.29 (6), p.587-594

2003

Link zum Volltext

Verfügbarkeit prüfen

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach

Diabetes, obesity & metabolism, 2008-12, Vol.10 (12), p.1212-1220

2008

Link zum Volltext

Verfügbarkeit prüfen

What a psychiatrist needs to know about diabetes

European psychiatry, 2005-12, Vol.20 (S4), p.S330-S334

Charbonnel, B.

2005

Link zum Volltext

Verfügbarkeit prüfen

Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17)

Diabetic medicine, 2009-10, Vol.26 (10), p.1033-1039

2009

Link zum Volltext

Verfügbarkeit prüfen

Fulminant type 1 diabetes in Caucasians: A report of three cases

Diabetes & metabolism, 2008-11, Vol.34 (5), p.529-532

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 552

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(425)
Mit Volltextzugriff
(369)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(252)
Science & Technology
(188)
Life Sciences & Biomedicine
(163)
Female
(148)
Male
(126)
Adult
(114)
Endocrinology & Metabolism
(104)
Middle Aged
(93)
Biological And Medical Sciences
(88)
Medical Sciences
(79)
Endocrinopathies
(74)
Aged
(67)
Hypoglycemic Agents - Therapeutic Use
(49)
Sciences Biologiques Et Medicales
(48)
Sciences Medicales
(48)
Diabetes Mellitus, Type 2 - Drug Therapy
(46)
Endocrine Pancreas. Apud Cells
(44)
Diabetes. Impaired Glucose Tolerance
(43)
Diabetes
(42)
Internal Medicine
(40)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: Results from the DIALOG study

Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal

A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial

Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings

After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?

Pharmacological management of type 2 diabetes: the potential of incretin-based therapies

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes

Efficacy and Safety of Pioglitazone Versus Metformin in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Randomized Trial

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes

CA-109: Conséquences d'une hypoglycémie sévère sur le contrôle glycémique dans le diabète : analyse du DCCT

Predicting severe hypoglycaemia with self-monitoring of blood glucose in type 1 diabetes

A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment

Insulin therapy for diabetes mellitus: Treatment regimens and associated costs

Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes

Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin? A randomized controlled trial of a DPP4 inhibitor versus insulin secretagogues

Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach

What a psychiatrist needs to know about diabetes

Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17)

Fulminant type 1 diabetes in Caucasians: A report of three cases

Suchergebnisse filtern